(Alliance News) - Faron Pharmaceuticals Oy on Thursday said data showed a patient had a 44% reduction in tumour size when receiving doses of its Clevegen antibody.
The findings were part of the Matins clinical trial on Clevegen.
Faron explained: "Data showed that the size of the target lesion tumour (a lung metastasis) reduced by 44% and other non-target lesions stabilised. Biochemical tumour load marker also declined and clearance of pleura fluid was observed."
Chief Executive Officer Markku Jalkanen added: "We are very encouraged to have a second partial target lesion responder in our dose finding part of the trial, suffering from a non-treatable melanoma and resistant to all existing anti-melanoma treatments, including immune checkpoint inhibitor combinations."
The patient has been removed from the trial, however, Faron added.
Scans revealed the patient had haemorrhagic brain metastases, which occurs when cancer cells spread to the brain.
Faron added: "These were not previously identified due to a lack of baseline brain scans prior to Clevegen administration and, according to the study protocol, resulted in the patient being removed from the trial. To prevent similar situations occurring in the future, the Matins study protocol has been amended to include baseline brain imaging to rule out existing brain metastases."
Shares in the company were 6.8% lower at 307.50 pence each in London on Thursday afternoon.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)